Search results for "diabetic nephropathy"

showing 4 items of 34 documents

Wine consumption and renal diseases: new perspectives.

2006

Investigations into the relation between wine consumption and kidney disease have been limited. Patients with chronic renal failure show accelerated atherosclerotic damage and, considering the well-known protective effect of wine on the cardiovascular system, moderate wine consumption might be advantageous. Oxidative stress and endothelial dysfunction, which are inter-related, play a role in the pathophysiology of many renal diseases, including acute and chronic renal failure. Ethanol and non-alcoholic wine components, especially polyphenols, influence oxidative balance and endothelial function. Although long-term alcohol abuse has been associated with many renal alterations in humans, in e…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismWinePharmacologyKidneyAntioxidantsNephropathyDiabetic nephropathyPhenolsInternal medicinemedicineHumansEndothelial dysfunctionFlavonoidsWineKidneyNutrition and DieteticsRenal ischemiabusiness.industryPolyphenolsfood and beveragesKidney metabolismmedicine.diseaseOxidative Stressmedicine.anatomical_structureEndocrinologyKidney Failure ChronicEndothelium VascularbusinessOxidation-ReductionKidney disease
researchProduct

Sodium-glucose cotransporter 2 inhibition : towards an indication to treat diabetic kidney disease

2020

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45mL/min/1.73m2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A r…

medicine.medical_specialtyMedicina030232 urology & nephrologyRenal functionReviewsType 2 diabetes030204 cardiovascular system & hematologyDiabetic nephropathy03 medical and health sciences0302 clinical medicineSodium-Glucose Transporter 2Internal medicineDiabetes mellitusDiabetic nephropathiesmedicineChronic renal failureHumansDiabetic NephropathiesDiabetic kidney diseaseESRDSodium-Glucose Transporter 2 InhibitorsTransplantationbusiness.industryType 2 diabetesNefropaties diabètiquesmedicine.diseasePrognosisBlood pressureDiabetes Mellitus Type 2NephrologyHeart failureSodium/Glucose Cotransporter 2Insuficiència renal crònicabusinessSGLT2 inhibitorsKidney disease
researchProduct

Diabetic Kidney Disease

2010

Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and end-stage renal disease (ESRD). Patients with diabetic nephropathy have a high burden of cardiovascular morbidity and mortality. Therefore, interventions that reduce the incidence and progression rate of DN will reduce morbidity and mortality rates as well as health care costs. Hyperglycemia and arterial hypertension are the two main risk factors for DN, but even in the presence of hyperglycemia and elevated blood pressure (BP) for long periods, DN develops only in susceptible patients. Family studies have confirmed the presence of hereditary factors in the development of DN. Besides these four key factors, others …

medicine.medical_specialtyProteinuriabusiness.industryMortality rateIncidence (epidemiology)Diseasemedicine.diseaseNephropathyDiabetic nephropathyDiabetes mellitusInternal medicineMedicinemedicine.symptombusinessIntensive care medicineKidney disease
researchProduct

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

2015

Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, renin angiotensin-aldosterone system blockade and multifactorial intervention. However, the renal protection provided by these therapeutic modalities is incomplete. There is a scarcity of studies analysing the nephroprotective effect of antihyperglycaemic drugs beyond their glucose lowering effect and improved glycaemic control on the prevention and progression of diabetic nephropathy. This article analyzes the exisiting data about older and newer drugs as well as the mechanisms associated with hypoglycemic drugs, apart from their well known blood gluc…

medicine.medical_specialtylcsh:MedicineReviewPharmacologyalbuminuriaDiabetic nephropathyDDP4 inhibitorsDiabetes mellitusantihyperglycemic drugsSGLT2 inhibitionRenin–angiotensin systemDiabetic nephropathiesmedicineIntensive care medicineGlycemicnephroprotectionKidneyDiabetisdiabetic chronic kidney diseasebusiness.industrydiabetic nephropathylcsh:RDiabetesGeneral MedicineNefropaties diabètiquesmedicine.diseaseBlockadeClinical trialmedicine.anatomical_structurediabetes mellitusAlbuminuriaglucagon-like peptide agonistsmedicine.symptombusiness
researchProduct